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Abstract
Background: Epigenetic aberrations and a CpG island methylator phenotype have been shown to be associated with 
poor outcomes in children with neuroblastoma (NB). Seven cancer related genes (THBS-1, CASP8, HIN-1, TIG-1, BLU, 
SPARC, and HIC-1) that have been shown to have epigenetic changes in adult cancers and play important roles in the 
regulation of angiogenesis, tumor growth, and apoptosis were analyzed to investigate the role epigenetic alterations 
play in determining NB phenotype.
Methods: Two NB cell lines (tumorigenic LA1-55n and non-tumorigenic LA1-5s) that differ in their ability to form 
colonies in soft agar and tumors in nude mice were used. Quantitative RNA expression analyses were performed on 
seven genes in LA1-5s, LA1-55n and 5-Aza-dC treated LA1-55n NB cell lines. The methylation status around THBS-1, 
HIN-1, TIG-1 and CASP8 promoters was examined using methylation specific PCR. Chromatin immunoprecipitation 
assay was used to examine histone modifications along the THBS-1 promoter. Luciferase assay was used to determine 
THBS-1 promoter activity. Cell proliferation assay was used to examine the effect of 5-Aza-dC on NB cell growth. The 
soft agar assay was used to determine the tumorigenicity.
Results: Promoter methylation values for THBS-1, HIN-1, TIG-1, and CASP8 were higher in LA1-55n cells compared to 
LA1-5s cells. Consistent with the promoter methylation status, lower levels of gene expression were detected in the 
LA1-55n cells. Histone marks associated with repressive chromatin states (H3K9Me3, H3K27Me3, and H3K4Me3) were 
identified in the THBS-1 promoter region in the LA1-55n cells, but not the LA1-5s cells. In contrast, the three histone 
codes associated with an active chromatin state (acetyl H3, acetyl H4, and H3K4Me3) were present in the THBS-1 
promoter region in LA1-5s cells, but not the LA1-55n cells, suggesting that an accessible chromatin structure is 
important for THBS-1 expression. We also show that 5-Aza-dC treatment of LA1-55n cells alters the DNA methylation 
status and the histone code in the THBS-1 promoter modifies cell morphology, and inhibits their ability to form colonies 
in soft agar.
Conclusion: Our results suggest that epigenetic aberrations contribute to NB phenotype, and that tumorigenic 
properties can be inhibited by reversing the epigenetic changes with 5-Aza-dC.
Background
The pediatric cancer neuroblastoma (NB) is character-
ized by a broad spectrum of clinical behavior, reflective of
the biologic heterogeneity of this neoplasm [1,2].
Although specific genetic abnormalities have been shown
to be predictive of the outcome in NB, recent studies have
indicated that epigenetic aberrations also contribute to
NB pathogenesis. Our group and others have shown that
poor outcome is associated with hypermethylation of a
number of tumor suppressor genes including RASSF1A,
CASP8, HIN-1, and DCR2 [3-5]. We have also demon-
strated that NB tumor growth is impaired following treat-
ment with drugs that inhibit histone deacetylase and/or
DNA methylation in preclinical models [6].
Biologic differences are commonly seen in NB cell lines
established from human NB tumors, and morphologi-
cally distinct cell types [neuroblastic (N-type) and sub-
strate-adherent (S-type)] have been extensively
characterized. N-type cells have small, rounded, loosely
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adherent cell bodies with numerous neurite-like pro-
cesses and express neuronal markers, such as tyrosine
hydroxylase. S-type cells are substrate-adherent large, flat
cells that resemble epithelial cells or fibroblasts and lack
neuronal markers [7,8]. Interestingly, purified N-type and
S-type NB cells can spontaneously interconvert from one
cell type to the other, suggesting that epigenetic changes
that are reversible may play a role in determining pheno-
type.
A CpG island methylator phenotype (CIMP) has been
shown to be predictive of poor outcome in a variety of
different cancers, including NB [9]. In studies by Abe and
coworkers, CIMP was detected in almost all MYCN-
amplified NB tumors, a genetic marker of poor prognosis.
However, CIMP was also shown to be predictive of poor
outcome in cases without MYCN amplification [10-12].
Further, in this study the prognostic influence of CIMP
and  MYCN-amplification was independent of age and
disease stage, both powerful clinical prognostic factors in
NB.
To further investigate the role epigenetic changes play
in determining NB phenotype, we analyzed the status of
promoter methylation and the level of expression of
seven genes with tumor suppressor function (THBS-1,
HIC-1, HIN-1 TIG-1, CASP8, BLU, and SPARC), that are
epigenetically silenced in subsets of adult cancers, in an
N-type tumorigenic NB cell line (LA1-55n) and an S-type
non-tumorigenic NB cell line (LA1-5s). Changes in NB
cell morphology and soft agar colony growth following
pharmacological reversal of the epigenetic aberrations
were also examined.
Methods
Cells and culture conditions
The biological and genetic characteristics of the NB cell
lines used in this study have been previously reported
[13]. NB cell lines were grown at 5% CO2 in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 10% heat-
inactivated fetal bovine serum (Invitrogen), L-Glutamine
and antibiotics.
5-Aza-dC and VPA treatment
Cells were treated with either the DNA methyltransferase
inhibitor 5-Aza-dC or the histone deacetylase inhibitor
VPA as shown in Table 1.
cDNA synthesis and SYBR green real-time PCR
RNA was isolated from untreated and 5-Aza-dC-treated
LA1-55n and LA1-5s cells using Trizol reagent (Invitro-
gen). Reverse transcription was performed using Super-
script III (Invitrogen) and 50 μM oligo(dT)20 at 50°C for
50 min. SYBR green real-time PCR reactions were set up
containing 1X Power SYBR Green Master Mix (Applied
Biosystems, Foster City, CA), 250 nM forward and
reverse primers in a 20 μl reaction. All assays were carried
out in a 96-well format. Real-time fluorescent detection
of PCR products was performed with an 7500 Fast Real-
Time PCR System (Applied Biosystems) using the follow-
ing thermocycling conditions: 1 cycle of 50°C for 2 min
and 95°C for 20 s; 40 cycles of 95°C for 30 s, and 60°C for
1 min. The primers and PCR conditions are shown in
Table 2. GAPDH was used as an endogenous control for
gene expression. For data analysis, the comparative
method (∇∇Ct) was used to calculate relative quantities
of a nucleic acid sequence. Non-treated LA1-55n cells
were used as the calibrator sample, and GAPDH was used
as an endogenous control detector.
DNA isolation and bisulfite modification
Total genomic DNA was extracted from the NB cell lines
using the Puregene Core Kit A (Qiagen, Valencia, CA)
and modified by sodium bisulfite using the CpGenome
DNA Modification Kit (Intergen Co., Purchase, NY).
Genomic DNA from normal human adrenal tissue was
purchased from BioChain Institute, Inc. (Hayward, CA).
As previously described [13], 1 μg of genomic DNA was
denatured by NaOH and modified by sodium bisulfite,
which converts all unmethylated cytosines to uracils. The
modified DNA was desulfonated with NaOH and puri-
fied.
DNA methylation analysis
DNA methylation degree was measured using real-time
quantitative methylation-specific PCR (QMSP). The real-
time PCR conditions were 95°C for 10 minutes, then 40
cycles at 95°C for 15 seconds, and 58°C to 60°C (depend-
ing on the primer set and/or optimization conditions) for
1 minute. Fluorescence data was collected during the
annealing/extension step for determining the cycle
Table 1: Conditions for 5-Aza-dC and VPA treatments
5-Aza-dC treatment
Experiment 5-Aza-dC (μM) time (days)
cell proliferation 0.01, 0.1, 1, 10, 100 3
gene expression 4 1
methylation study 4 1
ChIP assay 4 1
soft agar assay 0.5, 2.5, 10 2
soft agar assay 0.1, 1 7
morphology 0.1 14, 21
VPA treatment
Experiment VPA (mM) time (days)
ChIP assay 5 1Yang et al. BMC Cancer 2010, 10:286
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threshold (Ct). After amplification, melting curve analysis
was performed for PCR product identification that con-
sisted of one cycle of 95°C for 1 minute, 58-60°C for 30
seconds, and 95°C for 30 seconds, with data collection
throughout the linear increase of temperature from 58 to
95°C. Serial dilutions of the LA1-55n DNA template were
used to generate standard curves from Ct values to assess
the sensitivity, amplification efficiency, and linear range
for quantification. All real-time QMSP assays were per-
formed in duplicate or triplicate, and at least three inde-
pendent experiments were performed for each condition
tested. The primer sequences and conditions are shown
in Table 2. Both β-actin and MYOD1 were used as inter-
nal reference genes. Primers of the β-actin  and
MYOD1genes were located in an area without CpG
nucleotides; thus, amplification of β-actin and MYOD1
by QMSP occurs independently of a CpG island methyla-
tion status, whereas the amplification of THBS1, HIN1,
TIG1, and CASP8 is proportional to the degree of cyto-
sine methylation within their promoters.
Chromatin immunoprecipitation (ChIP) assay
NB cells (1 × 107) were treated with 1% formaldehyde for
10 min to crosslink histones to DNA. After washing with
cold PBS, the cell pellets were resuspended in a cell lysis
buffer (10 mM Tris, pH8.0, 10 mM NaCl, 0.2% NP40).
Nuclei were resuspended in nuclei lysis buffer (50 mM
Tris pH 8.0, 10 mM EDTA, 1% SDS) and sonicated 15
min for LA1-55n and 20 min for LA1-5s cells. The solu-
ble chromatin fraction was collected, and 5 μl of antibody
for acetyl-H3 (Upstate, Waltham, MA), acetyl-H4
(Upstate), trimethyl-H3-K4 (Abcam, Cambridge, MA),
trimethyl-H3-K9 (Upstate), trimethyl-H3-K27 (Upstate),
dimethyl-H3-K27 (Abcam), or normal rabbit IgG was
added. After incubation, chromatin-antibody complexes
were collected using salmon sperm DNA/protein A aga-
rose beads (Upstate). After washing, immunoprecipitated
DNA was treated with RNase and the crosslinks were
then reversed by heating the samples at 65°C for 6 h.
DNA was extracted with a QIAquick PCR Purification kit
(Qiagen) and analyzed by SYBR green real-time PCR.
Table 2: Primer sequences for PCR
Gene Purpose Sense primer Antisense primer
BLU Q-PCR CACGAGGCCTCCATCATCA ACTCACACACCTCCTTGTGGAA
CASP8 Q-PCR TGCAGAGGGAACCTGGTACAT TCGAGGACATCGCTCTCTCA
GAPDH Q-PCR CCATGGGGAAGGTGAAGGTCGGACTC GGTGGTGCAGGCATTGCTGATG
HIC-1 Q-PCR TGCTGCAGCTCAACAACCA GGCGTTCTGCACCACGAT
HIN-1 Q-PCR CACCCTCAACCCGCTGAA ACACTTCTGGGAGCCCTCTATG
SPARC Q-PCR TCTTCCCTGTACACTGGCAGTTC AGCTCGGTGTGGGAGAGGTA
THBS1 Q-PCR TGGAACTATGGGCTTGAGAAAAC CACTGATGCAAGCACAGAAAAGA
TIG-1 Q-PCR CCTGGCAAACCTCTTAAAGTGAA GGAGGCTTCTTCTGGTGTCTGT
Actin QMSP TGGTGATGGAGGAGGTTTAGTAAGT AACCAATAAAACCTACTCCTCCCTTAA
BLU QMSP GTAGTTATGGAAACGGGTTAGTC CGCTAAAAATCCAAATACTATAACG
CASP8 QMSP AGGTAGGAGAATCGTTTGAATTC AACGAAATTTCGCTCTTATTACC
HIC-1 QMSP GTTAGGCGGTTAGGGCGTC CCGAACGCCTCCATCGTAT
HIN-1 QMSP AGGGACGATTAGGTTTTATTTTC CTAATTTCGAAAACAAAAAAACG
MYOD1 QMSP CCAACTCCAAATCCCCTCTCTAT TGATTAATTTAGATTGGGTTTAGAGAAGGA
SPARC QMSP GTTGTTATATTCGGGGACGAC TAACCCGTTTCCATAACTACGA
THBS1 QMSP GAAAGGGTTCGAAGGTAGC CCGAACGCCTATCCTAAA
TIG-1 QMSP GTTTAGTGTTAGGATGCGGTATC AAAACGCGATACGAAATAACA
THBS1 ChIP-1 ATGACAACTTGGCAAAAAAGAGAA GGCCGAAGTGATGGACCTT
THBS1 ChIP-2 AATGTGGGTGAATTCCTGTTAAGG GGGTGGAAAGGAAAGGTCATAGA
THBS1 ChIP-3 TGGGTGCCGATTCCAGAA TCCCGCAAATCATAGGTAATGA
THBS1 ChIP-4 CCACGCAAGAAAAGCGAAA TGCTGCAAACAGCCAAGTG
THBS1 ChIP-5 GGGCAGGTACTTTAACGAATGG CTGGGCCCGTTTTGTAAAAA
THBS1 ChIP-6 GGCGGGCACCGACTTT GCGCAACTTTCCAGCTAGAAAYang et al. BMC Cancer 2010, 10:286
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The primer pairs used for ChIP assays are also shown in
Table 2.
Luciferase assays
A series of THBS-1 reporter plasmids [13] were used to
determine the THBS-1 promoter activity. LA1-55n and
LA1-5s cells were seeded in a 24-well dish and grown to
90% confluence in the growth medium. For each well, 0.5
μg of reporter construct was cotransfected with 25 ng of
the Renilla luciferase plasmid, pRL-CMV (Promega,
Madison, WI), into NB cells using Lipofectamine2000
(Invitrogen). Cells were harvested 36 h after transfection,
and the reporter activity for the two cell lines was mea-
sured at the same time using the Dual Luciferase Assay
(Promega) according to the manufacturer's instructions.
Experimental luciferase activities were normalized for
efficiency against control Renilla luciferase readings.
Cell proliferation, examination of morphological alteration, 
and soft agar clonogenic assay
MTS colorimetric assays were performed to measure cell
proliferation. Briefly, LA1-55n cells were seeded into 96-
well plates at a density of 5 × 103 cells/well. After 24 h, 5-
Aza-dC was added at various concentrations to each qua-
druplicate well. After 72 h treatment, MTS labeling mix-
ture (Promega) was added, and cells were further
incubated for 3 h. The absorbance of the samples was
measured using a Bio-Kinetics Microplate Reader (Bio-
T ek Instruments, W inooski, VT). Percentage of N-type
cells with or without treatment with 5-Aza-dC was
obtained by quantifying 5 consecutive high power fields.
Anchorage-independent growth was assayed by colony
formation on soft agar. Briefly, approximately 2 × 103 cells
from the 5-Aza-dC treated and nontreated LA1-55n cells
and LA1-5s cells were plated on an upper layer of 0.3%
Bacto-Agar in RPMI 1640 and 20% fetal bovine serum
over an underlayer of 0.51% Bacto-Agar with 20% fetal
bovine serum, RPMI 1640, and antibiotics in a 35-mm
dish as described previously [14]. Colonies were counted
on day 28.
Statistical analyses
Statistical analyses were performed using a two-tailed
Student's t test. A p value of ≤ 0.05 was considered statis-
tically significant.
Results
Expression analysis of cancer related genes
To investigate the relationship between epigenetic
changes and NB phenotype, we analyzed the level of
expression of seven genes with tumor suppressor func-
tion that are epigenetically silenced in a variety of adult
and pediatric cancers (THBS-1, HIC-1, HIN-1 TIG-1,
CASP8, BLU, and SPARC), in a tumorigenic N-type NB
cell line (LA1-55n) and a non-tumorigenic S-type cell line
(LA1-5s). Lower levels of THBS-1, SPARC, HIC-1, HIN-1,
TIG-1 and CASP8 expression were detected in the tum-
origenic LA1-55n cells compared to non-tumorigenic
LA1-5s cells (Figure 1A). No difference in the level of
BLU gene expression was seen.
Treatment with 5-Aza-dC restores gene expression
To test if the decreased levels of gene expression detected
in the tumorigenic LA1-55n cells were due to promoter
hypermethylation, the level of gene expression was exam-
ined in LA1-55n cells following treatment with 5-Aza-
dC, a DNA-methyltransferase inhibitor. As shown in Fig-
ure 1B, the level of expression of five of the genes (HIN-1,
CASP8,  HIC-1,  THBS-1, and TIG-1) was upregulated
with 4 μM of 5-Aza-dC treatment at 24 h. This dose and
time point has previously been shown to restore gene
expression in NB cells [13]. THBS-1 was especially sensi-
tive to 5-Aza-dC treatment, and the level of transcript
expression was increased by 20 folds following 24 h of
treatment. However, no significant upregulation of BLU
and SPARC was seen following 24 h of 5-Aza-dC treat-
ment.
DNA methylation profiling of cytosine methylation
To examine the status of promoter DNA methylation of
these genes in the tumorigenic LA1-55n and non-tumori-
genic LA1-5s NB cells, quantitative methylation analysis
was performed for the promoter regions of four genes. As
s hown in F igur e  2, w e  f ound a  highe r degr ee  of  DNA
methylation within the THBS-1, CASP8, HIN-1, and TIG-
1  promoters in tumorigenic LA1-55n cells versus the
non-tumorigenic LA1-5s cells. In addition, the methyla-
tion degree for the promoter regions of four genes was
decreased after treatment with 5-Aza-dC.
THBS-1 promoter histone acetylation and methylation
To investigate if histone modifications contributed to the
significant differences in THBS-1 expression levels in the
tumorigenic versus non-tumorigenic NB cells, we ana-
lyzed histone marks along the THBS-1  promoter. As
shown in Figure 3, acetylated H3 (acetyl H3), acetylated
H4 (acetyl H4), and H3K4Me3 marks associated with an
open chromatin state, are enriched in the THBS-1 pro-
moter regions in the non-tumorigenic LA1-5s cells that
express high levels of this gene. However, consistent with
the low levels of THBS-1 expression in the tumorigenic
NB cells, an enrichment of marks associated with a closed
chromatin state (H3K9Me3, H3K27Me3, andYang et al. BMC Cancer 2010, 10:286
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H3K27Me2) are present in THBS-1 promoter in the LA1-
55n cells.
We also performed detailed mapping of histone acety-
lation and histone methylation across a 1.2 kb region of
the THBS-1 promoter in the tumorigenic LA1-55n and
non-tumorigenic LA1-5s NB cell lines using the ChIP
assay (Figure 4A). Overall, acetylated histone H3 and H4
were enriched throughout the unmethylated THBS-1
promoter in the non-tumorigenic LA1-5s cells. In con-
trast, there was no acetylation of these sites along the
hypermethylated promoter in the tumorigenic LA1-55n
cells (Figure 4B and 4C). A similar pattern of acetylation
in the THBS-1 promoter in the NB cells lines was seen for
H3K4Me3 (Figure 4D). In contrast, the three histone
codes associated with a repressive chromatin state
(H3K9Me3, H3K27Me3, H3K27Me3) were enriched
along the entire hypermethylated THBS-1 promoter in
tumorigenic LA1-55n cells (Figure 4E, F, G).
Figure 1 Cancer related gene expression in tumorigenic, non-tu-
morigenic, and 5Aza-dC treated tumorigenic NB cell lines. A, 
Quantitative RT-PCR analysis of RNA expression of seven cancer related 
genes was performed in tumorigenic LA1-55n and non-tumorigenic 
LA1-5s NB cell lines. GAPDH was used as an endogenous control. B, 
LA1-55n cells were treated with 4 μM 5-Aza-dC for 1 day. Quantitative 
RT-PCR analysis of seven cancer related genes was performed in tum-
origenic LA1-55n treated with 5-Aza-dC. GAPDH was used as an endog-
enous control.
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Figure 2 Alteration of DNA methylation degree after treatment 
with 5-Aza-dC. Genomic DNA from LA1-55n, LA1-5s, and LA1-55n 
treated with 4 μM 5-Aza-dC was isolated and modified by sodium 
bisulfite. Quantitative methylation-specific PCR was performed to ex-
amine the methylation degree around promoter regions for four can-
cer related genes (THBS-1, HIN-1, TIG-1, and CASP8) in LA1-55n, LA1-5s 
as well as LA1-55n cells treated with 5-Aza-dC.
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Treatment with 5-Aza-dC induces histone modifications in 
the THBS-1 promoter
In a previous study, we showed that administration of the
HDAC inhibitor valproic acid (VPA) changed gene
expression in NB cells [6]. The cells were treated with 1
mM VPA for 2-48 h. Based on these results, we treated
the tumorigenic LA1-55n cells with 5mM VPA for 1 day
and investigated its effects on histone modifications.
Unexpectantly, the ChIP assays revealed that VPA treat-
ment alone did not induce an enrichment of markers
associated with open chromatin state along the THBS-1
promoter region. Furthermore, VPA treatment did not
decrease an enrichment of marks associated with closed
chromatin state, except for H3K27Me3 (Figure 5A).
To determine the relation between DNA methylation
and histone modification, we next tested the effects of 5-
Aza-dC, an inhibitor of DNMT, on the histone marks,
and found that this DNA methyltransferase inhibitor did
induce histone modifications. Following treatment of the
tumorigenic LA1-55n cells with 5-Aza-dC, the levels of
H3K9Me3, H3K27Me3, and H3K27Me2 were severely
depleted (Figure 5B). Whereas the level of acetylated
H3K4Me3,acetyl H3, and acetyl H4 along the THBS-1
promoter region was markedly enriched after 3 d treat-
ment with 5-Aza-dC (Figure 5C). After 24 h of 5-Aza-dC-
treatment, only the enrichment of H3K4Me3 is observed.
Figure 4 Histone code map of THBS-1 promoter region. ChIP assay was performed on tumorigenic LA1-55n and non-tumorigenic LA1-5s cells. A, 
Schematic of the THBS-1 promoter. The vertical lines represent the location of CpG dinucleotide, and the orange line indicates the CpG island of the 
THBS-1 promoter region. The horizontal bars below the schematic indicate the location of the DNA fragments amplified by Q-PCR done on DNA re-
covered from ChIP experiments. B, C, and D, The enrichment of THBS-1 promoter DNA immunoprecipitated with antibodies specific for acetylated H3, 
acetyl H4, and H3K4Me3, respectively in LA1-5s cells. E, F, and G, The enrichment of THBS-1 promoter DNA immunoprecipitated with antibodies spe-
cific for H3K9Me3, H3K27Me3, and H3K27Me2, respectively in LA1-55n cells.
37657771  37660771
Chr 15
1        2                            3              4           5           6
A
B
C
D
E
F
G
Transcriptional 
start site
Acetyl H3
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1 2 345 6
LA1-55n
LA1-5s
Acetyl H4
-0.2
0
0.2
0.4
0.6
0.8
1 2 345 6
LA1-55n
LA1-5s
H3K4Me3
-0.2
0
0.2
0.4
0.6
0.8
1 2 345 6
LA1-55n
LA1-5s
H3K9Me3
0
0.2
0.4
0.6
1 2 345 6
LA1-55n
LA1-5s
H3K27Me3
-0.04
0
0.04
0.08
0.12
0.16
1 2 345 6
LA1-55n
LA1-5s
H3K27Me2
0
0.05
0.1
0.15
0.2
0.25
1 2 345 6
LA1-55n
LA1-5s
A
c
e
t
y
l
 
H
3
 
e
n
r
i
c
h
m
e
n
t
A
c
e
t
y
l
 
H
4
 
e
n
r
i
c
h
m
e
n
t
H
3
K
4
M
e
3
 
e
n
r
i
c
h
m
e
n
t
H
3
K
9
M
e
3
 
e
n
r
i
c
h
m
e
n
t
H
3
K
2
7
M
e
3
 
e
n
r
i
c
h
m
e
n
t
H
3
K
2
7
M
e
2
 
e
n
r
i
c
h
m
e
n
t
PositionP ositionYang et al. BMC Cancer 2010, 10:286
http://www.biomedcentral.com/1471-2407/10/286
Page 7 of 10
THBS-1 promoter activity
To investigate if THBS-1 promoter activity contributed to
the difference of THBS-1 expression in the tumorigenic
LA1-55n versus non-tumorigenic LA1-5s cells, a series of
THBS-1  luciferase/promoter reporter constructs were
used and transiently transfected into the phenotypically
distinct NB cell lines (LA1-55n and LA1-5s). As shown in
Figure 5D, no significant difference in the activity of the
THBS-1 promoter was seen in the cell lines, indicating
that transcriptional factors are functional in both NB cell
lines. Thus, the disparate levels of THBS-1 expression in
the LA1-55n and LA1-5s cells are not due to differences
in promoter activity of THBS-1 in the tumorigenic LA1-
55n and non-tumorigenic LA1-5s cells.
Figure 5 Alteration of histone marks around THBS-1 promoter region. A, ChIP/quantitative PCR was performed around THBS-1 promoter region 
in LA1-55n and VPA-treated LA1-55n cells. B, ChIP/quantitative PCR was performed around THBS-1 promoter region in 5-Aza-dC treated and non-treat-
ed LA1-55n cells. The enrichment of three histone marks related to repressive chromatin state is markedly reduced in 5-Aza-dC treated LA1-55n cells 
compared with untreated ones. C, ChIP assay was performed around THBS-1 promoter region in 5-Aza-dC treated and non-treated LA1-55n cells. D, 
Luciferase assay was performed to examine the promoter activity of THBS-1 between LA1-55n and LA1-5s cells.
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5-Aza-dC treatment modifies the tumorigenic phenotype 
of LA1-55n NB cells
To investigate if reversal of the epigenetic aberrations in
the tumorigenic LA1-55n cells with 5-Aza-dC treatment
was sufficient to induce changes in phenotype, we first
examined its effects on cell proliferation. We found that
the treatment inhibited the proliferation of LA1-55n NB
cells in vitro in a dose-dependent manner, with an ID50 of
10 μM (Figure 6A). We next assessed whether treatment
with 5-Aza-dC would induce changes in the morphology
of the N-type LA1-55n cells. For these studies, the cells
were treated with 0.1 μM 5-Aza-dC, a dose that is not
cytotoxic. Following 21 days of 5-Aza-dC treatment, sub-
strate-adherent cells, resembling S-type NB cells, were
seen (Figure 6B, as shown with arrows), and the number
of cells with neurites decreased by ~20% (p = 0.0062)
(Figure 6C). Treatment with 5-Aza-dC also decreased the
ability of LA1-55n to form colonies in soft agar in a dose
dependent manner (Figure 6D). At a concentration of 10
μM, the ID50, the number of colonies was decreased by
95% compared to controls (p < 0.001). The colony forma-
tion was markedly decreased after 7 days of treatment
even at concentrations of 0.1 μM (p < 0.001). As expected,
the non-tumorigenic NB cell line, LA1-5s did not form
colonies on the soft agar.
Discussion
Epigenetic changes play an important role in the patho-
genesis of cancer, and a CpG island methylator phenotype
has been shown to be predictive of poor outcome. To
Figure 6 Effect of 5-Aza-dC on NB growth and tumorigenicity in vitro. A, In vitro cell proliferation assay demonstrating dose-response effects of 
5-Aza-dC on LA1-55n cells. Each point represents the mean of four replicate experiments. B, Morphological alteration after treatment with 5-Aza-dC. 
LA1-55n cells were treated with 0.1 μM of 5-Aza-dC for 14 and 21 days respectively. Top photos (a and b) show the morphology of nontreated LA1-
55n cells. Middle photos (c and d) show the morphology of LA1-55n cells treated with 5-Aza-dC for 14 days. Bottom photos (e and f) show the mor-
phology of LA1-55n cells treated with 5-Aza-dC for 21 days. Green arrows indicated the flat "S" type cells. C, Quantitative analysis of percentage of N- 
type cells after treatment with 5-Aza-dC for 14 and 21 days. D, Quantitative analysis of colony formation on soft agar for 5-Aza-dC treated and untreat-
ed NB cells. Colonies were counted under a microscope. The average number of colonies was calculated and is shown as a percentage of the average 
number of colonies in the untreated group per cell line. Error bars represent standard deviation of colony numbers between different plates for each 
group.
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investigate if epigenetic aberrations contribute to NB
phenotype, we examined the methylation status and level
of expression of seven genes with known tumor suppres-
sor function (HIC-1, TIG-1, HIN-1, CASP8, THBS-1,
SPARC, and BLU) in a N-type tumorigenic NB cell line
(LA1-55n) and an S-type, non-tumorigenic NB cell line
(LA1-5s). We show that the tumorigenic LA1-55n cells
have higher levels of promoter methylation and lower lev-
els of expression of five of the genes (THBS-1, HIC-1,
HIN-1, TIG-1, and CASP8) compared to the non-tumori-
genic LA1-5s cells. We also show that cell morphology
and phenotype of the tumorigenic LA1-55n cells are
modified following treatment with the demethylating
agent 5-Aza-dC.
Each of the genes analyzed in this study has previously
been shown to be epigenetically silenced in other types of
cancer, and in some cases, the presence of abnormal pro-
moter methylation has been shown to be associated with
a more aggressive phenotype in adult or pediatric can-
cers. SPARC is an extracellular matrix protein that has
been shown to function as an inhibitor of angiogenesis
[15], and in lung adenocarcinomas SPARC methylation
has been correlated with a negative prognosis [16].
Athough disparate levels of SPARC expression was seen
in the NB cell lines, there was no evidence of SPARC
methylation in the NB cells, indicating that alternative
mechanisms regulate SPARC expression in NB. In con-
trast, we did find higher levels of methylation of the pro-
apoptotic gene CASP8 in the tumorigenic LA1-55n cells,
which is consistent with the association between CASP8
methylation and high-risk disease and poor outcome that
has been reported in primary NB tumors [4]. BLU func-
tions as a tumor supressor in many cancer types [17]. In
human nasopharyngeal carcinoma, the frequency of BLU
promoter methylation was much higher compared with
non-neoplastic nasopharyngeal epithelia [18]. However,
we found no significant difference in the level of expres-
sion of this gene in the NB cell lines.
HIC-1  is a newly discovered tumor suppressor and
transcriptional repressor which is located at 17p13.3, a
region which frequently undergoes allelic loss in human
cancers [19]. A recent study indicated that HIC-1 is a cen-
tral molecule in a novel mechanism controlling cell
growth and that the disruption of the HIC-1 mediated
pathway may lead to abnormal cell proliferation [20].
Moreover, low to undetected expression of HIC-1 is asso-
ciated with poor outcome in breast cancer [21]. In this
study, expression of HIC-1 is higher in non-tumorigenic
NB cells compared with tumorigenic cells.
TIG-1, which has been linked to retinoic acid signaling,
was shown to be downregulated in many cancers [22,23].
Forced expression of TIG1  in cancer cells results in
decreased invasiveness and tumorigenicity, indicating
that diminished expression of TIG1  is involved in the
malignant progression of cancer. Our study showed that
lower level expression of TIG-1 in tumorigenic NB cells is
associated with hypermethylation of its promoter. HIN-1
is a putative cytokine with growth inhibitory activities.
HIN-1 was initially found to be significantly downregu-
lated in human breast carcinomas and in preinvasive
lesions. HIN-1 is a potent inhibitor of anchorage-depen-
dent and anchorage-independent cell growth, cell migra-
tion, and invasion [24,25]. Our previous study indicated
that methylation of HIN-1 is associated with poor out-
come in NB [4]. In this study we showed that the methy-
lation degree of HIN-1 promoter region is much higher in
tumorigenic NB cells compared with non-tumorigenic
NB cells.
Because of the remarkable up-regulation of THBS-1
expression that was seen in the LA1-55n cells following
treatment with 5-Aza-dC, we performed additional stud-
ies examining the histone marks along the promoter
regions of this gene in the NB cell lines. Histone marks
associated with a repressive chromatin state (H3K9Me3,
H3K27Me3, and H3K4Me3) were detected in the tumori-
genic LA1-55n cells, whereas histone codes associated
with an active chromatin state (acetyl H3, acetyl H4, and
H3K4Me3) were present in non-tumorigenic LA1-5s
cells. THBS-1 is a well-known natural inhibitor of angio-
genesis, and down-regulation of THBS-1 plays a critical
role in the angiogenic switch in several tumor types. We
have previously shown that the THBS-1  promoter is
methylated and silenced in tumorigenic NB cell lines and
in a cohort of NB primary tumors [13]. In this study, we
compiled a detailed map of histone acetylation and meth-
ylation across a 1.2 kb region of the THBS-1 promoter
which indicates that histone acetylation also plays an
important role in regulating THBS-1 expression. Further-
more, the results of our ChIP assay indicate that an acces-
sible chromatin structure is important in THBS-1
expression. To our knowledge, this is the first report
showing that THBS-1 expression is regulated by histone
modification. Our results further suggest that the altera-
tion of key parameters of the histone code depend upon
inhibition of the DNMTs, and DNA hypermethylation
mediated by DNMTs may be essential for maintaining a
particular combination of histone modifications at gene
promoters silenced with aberrant DNA methylation.
Conclusion
Taken together, our results indicate that epigenetic gene
silencing contributes to NB phenotype and that by restor-
ing the expression of tumor suppressor genes, 5-Aza-dC
can inhibit tumorigenic properties of NB cells. Additional
experiments investigating the global changes in gene
methylation and expression in control and 5-Aza-dC-
treated NB cells are needed to identify the cellular path-
ways that are modified by this treatment that influenceYang et al. BMC Cancer 2010, 10:286
http://www.biomedcentral.com/1471-2407/10/286
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NB phenotype. Further studies investigating the anti-NB
effects of agents capable of reversing these epigenetic
changes are warranted.
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